Posted by Michael Wonder on 23 Sep 2019
Novo prices oral Rybelsus on par with injectable rivals, ending discount fears
23 September 2019 - Monday morning, Bernstein analyst Wimal Kapadia echoed what many industry watchers were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”
After a Friday FDA approval, the Danish drugmaker unveiled the oral GLP-1’s list price of $26 per day, or $772 per 30 tablets across all doses—a price that’s “in-line with injectables” from that same class, Kapadia wrote in a note to clients.
